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PIN66
Cost Per Cure of telaPrevIr aNd BoCePrevIr IN treatmeNt-Naïve 
GeNotyPe 1 HePatItIs C PatIeNts wItH f2 fIBrosIs IN BrazIl
Morais A.D., Pereira M.L.
Janssen Cilag Farmaceutica, São Paulo, Brazil
Objectives: Compare the cost per cure of telaprevir of peginterferon and ribavirin 
(TVR+PR) compared to boceprevir plus peginterferon and ribavirin (BOC+PR) in 
the treatment of METAVIR scale F2 patients with previously untreated chronic 
hepatitis C genotype 1 in the Brazilian public (SUS) and private (SS) health care 
system. MethOds: Treatment costs considered drug acquisition costs of TVR+PR 
and BOC+PR from a public and private payer perspective in Brazil. The cost/cure 
was defined as the cost/sustained virological response (SVR) according to the 
phase 3 trials of TVR and BOC. The SVR rate for TVR+PR was defined as 79% and 
49% for PR in patients with F2 fibrosis. Based on the SPRINT-2 trial, the SVR-rate 
for F2 patients treated with BOC+PR was assumed 57%, average between F0/F1 
and F3/F4 patients, compared to 38% for PR. Treatment duration, based on the 
extended rapid virological response (eRVR), was taken from the respective trials 
of BOC (eRVR = 44%) and TVR (eRVR = 58%). Deterministic sensitivity analysis 
was carried out for the eRVR rate. Results: In the SUS, TVR+PR had an average 
treatment cost of R$ 40.093 per F2 fibrosis patient compared to R$ 36.185 with 
BOC+PR. Considering the SVR rate and the sensitivity analysis, TVR+PR had a 
cost/SVR of R$ 50.751 (R$ 49.797-R$ 51.705) compared to R$ 63.481 (R$ 61.771-R$ 
65.191) with BOC+PR. In the private health care system, TVR+PR had a treatment 
cost of R$ R$ 88.508 per F2 fibrosis patient compared to R$ 82.518 with BOC+PR. 
Considering the cost/SVR and sensitivity analysis, TVR+PR had a cost/SVR of R$ 
112.036 (R$ 108.253-R$ 115.819) compared to BOC+PR with a cost/SVR of R$ 144.768 
(R$ 140.631-R$ 148.905) per F2 patient in the SS. cOnclusiOns: Compared to 
BOC+PR, TVR+PR was a more cost-effective treatment of F2 fibrosis patients in 
both public and private health care systems.
PIN67
Cost-effeCtIveNess of PeGINterferoN alfa aNd rIBavIrIN for tHe 
treatmeNt of CHIldreN aNd youNG PeoPle wItH CHroNIC HePatItIs C 
from tHe PersPeCtIve of tHe NHs IN eNGlaNd aNd wales
Lion M.1, McCann E.1, Jiang Y.2
1MSD Ltd., Hoddesdon, UK, 2Amaris, London, UK
Objectives: To evaluate the cost-effectiveness of peginterferon (PEG INF) alfa and riba-
virin for the treatment of children and young people ages 3 to 17 years with Chronic 
Hepatitis C (CHC), from the perspective of the NHS in England and Wales. This analysis 
was submitted to NICE as part of a submission dossier for the multiple technology 
appraisal of PEG INF alfa and ribavirin for the respective population. MethOds: A 
Markov model was developed based on previous economic evaluations for treatment 
of adults with CHC with PEG INF alfa and ribavirin. The model evaluated the cost-effec-
tiveness of PEG INF alfa-2a or alfa-2b and ribavirin, and supportive care, for the treatment 
of people aged 5 to 17 years. An additional analysis was conducted on 3 and 4 year olds 
comparing supportive care to PEG INF alfa-2b and ribavirin in line with license. The 
cost-effectiveness was evaluated using the incremental cost-effectiveness ratio (ICER) 
from the perspective of the NHS over a lifetime horizon. The results were assessed 
overall and by age and genotype subgroups. Results: The results reported that both 
combinations of PEG INF alfa and ribavirin dominated supportive care for all patients. 
Driven by small variation in the comparative efficacy and costs, the comparison between 
PEG INF alfa-2a and alfa-2b, in combination with ribavirin, showed that PEG INF alfa-2b 
dominated PEG INF alfa-2a overall and in the following subgroups: 5 to 8 years, 14 to17 
years and genotypes 2/3. The ICER for the 9 to13 years subgroup was £4,697. PEG INF 
alfa-2a dominated PEG INF alfa-2b for the other genotype subgroup cOnclusiOns: The 
results of the economic evaluation demonstrated that treatment with either combina-
tion of PEG INF alfa and ribavirin is a cost-effective treatment option for children and 
young people aged 3 to 17 years with CHC.
PIN68
Cost-effeCtIveNess of 13-valeNt versus 10-valeNt PNeumoCoCCal 
CoNjuGate vaCCINe use IN tHe CzeCH NatIoNal ImmuNIzatIoN ProGram
Tichopad A.1, Vitova V.1, Roberts C.S.2, Hájek P.3
1CEEOR s.r.o., Prague, Czech Republic, 2Pfizer, New York, NY, USA, 3Pfizer, Praha, Czech Republic
Objectives: Streptococcus pneumoniae is presumed to be the major etiology 
agent responsible for a significant amount of meningitis, bacteremia and sepsis 
(invasive pneumococcal disease; IPD) as well as Community Acquired Pneumonia 
(CAP) and Acute Otitis Media (AOM). The Czech Republic (CR), as well as many 
other European countries have only a limited local evidence on the underlying 
epidemiology. The objective was to estimate the expected outcomes, costs, cost-
effectiveness of the pediatric national immunization program (NIP) with 13-valent 
pneumococcal conjugated vaccine (PCV13) and 10-valent pneumococcal conju-
gated vaccine (PCV10) as a comparator among specific populations of children 
and adults in preventing and reducing the incidence of IPD, CAP and AOM in 
CR. MethOds: A Markov decision-analytic model was developed to examine 
impacts of infant vaccination with PCV13 versus PCV10. PCV13 direct effectiveness 
was extrapolated from PCV7 efficacy data from clinical trials, using assumptions 
regarding serotype prevalence and PCV13 protection against additional serotypes, 
while indirect (herd) effect was extrapolated from US surveillance data following 
universal PCV7 use. The local epidemiology and cost data were used to achieve 
maximum national specificity. Results: Model predicts incremental EUR 64.5 
million for the PCV13 NIP from the payer’s perspective in the 10-year horizon, as 
compared to PCV10. This would lead to an reduction in IPD, all cause inpatient and 
outpatient CAP and AOM by approximately 921, 22 900, 56 796 and 40 598 cases, 
respectively, thus savings EUR 35.4 million. This gives a total cost of EUR 29.0 mil-
lion in the 10 years. The incremental cost per LYG or QALY gained is estimated 
as EUR 929 or EUR 1 164, respectively, from the payer’s perspective as compared 
to PCV10. cOnclusiOns: Comparing the national GDP per capita with the WHO 
Objectives: To estimate the cost-effectiveness (CE) of the 3 echinocandins 
(Anidulafungin, Caspofungin and Micafungin) and generic Fluconazole in the treatment 
of adult non-neutropaenic patients with invasive candidiasis (IC) in a Spanish Intensive 
Care Unit (ICU) setting. MethOds: A 4 arm decision tree model was developed with the 
3 echinocandins and generic Fluconazole as first line treatment. In case of treatment 
failure, a 2nd line treatment was administered (Liposomal Amphotericin-B following 
the echinocandins and either one of the 3 echinocandins for Fluconazole arm). After 2nd 
line failure, treatment was discontinued. Total treatment length was 14 days. Efficacy 
and safety (adverse events/lack of efficacy) parameters where obtained from a mixed-
treatment-comparison and a meta-analysis respectively. Efficacy was considered as 
first line success (Anidulafungin 75.32%; Micafungin 71.65%; Caspofungin 70.62%; and 
Fluconazole 56.7%). Length of the first and the second line were elicited using experts’ 
opinion through Delphi methodology. Daily drug acquisition costs were considered 
only. The CE was expressed as an incremental cost-effectiveness ratio (ICER). Univariate 
sensitivity analyses were also applied and included, length of treatment in 1st or 2nd line 
and finally drug dosages calculated as per SmPC recommendations according to dif-
ferent patient characteristics. Results: Total costs of IC treatment for Anidulafungin, 
Micafungin, Caspofungin and Fluconazole were € 5,552; € 5,985; € 6,350; € 1,654 respec-
tively. Anidulafungin was dominant compared to Micafungin and Caspofungin. 
Anidulafungin and Micafungin were cost-effective (€ 20,934; 29.576€ respectively) 
compared to Fluconazole (CE threshold of € 30,000). Sensitivity analyses revealed that 
ICER was sensitive to increases in the length of the 1st and 2nd line treatments, although 
Anidulafungin was cost-effective in all scenarios. cOnclusiOns: Based on the model’s 
assumptions, Anidulafungin is cost-saving compared to Micafungin and Caspofungin 
and cost-effective vs. Fluconazole in the treatment of patients with confirmed invasive 
candidiasis from a Spanish Hospital ICU perspective.
PIN64
Cost-effeCtIveNess of lINezolId versus vaNComyCIN IN tHe 
treatmeNt of veNtIlator assoCIated PNeumoNIa IN jamaICa
Garita M.1, Nicholson A.2, Cuesta G.3, Mould J.4
1Pfizer Central America and Caribbean, Escazu, San Jose, Costa Rica, 2University Hospital of the 
West Indies, Kingston, Jamaica, 3Pfizer Central America and the Caribbean, Escazú, San Jose, 
Costa Rica, 4Pfizer, New York, NY, USA
Objectives: The ventilator associated pneumonia (VAP) refers to the pneumonia 
that appears after 48-72 hours of endotracheal intubation and is the most common 
nosocomial infections in patients receiving mechanical ventilation. Late-onset VAP 
is responsible for prolonged ICU stay and higher mortality rates (24 to 50% and can 
even increase to 76%), which explains the importance of using more effective anti-
biotics depending on the severity of each case. The aim of this study is to assess 
the cost-effectiveness (CE) of linezolid against vancomycin in the treatment of VAP, 
from the public health care perspective. MethOds: A cohort of patients with VAP 
was simulated using a decision-tree model to compare costs and effectiveness of 
linezolid (600 mg/12 hours) and vancomycin (1 g/12 hours). Effectiveness measures 
were: microbiological success rates, mortality rates, and ICU and ward LOS. The model 
used a 12-week time horizon and only direct medical costs were considered (inpatient 
costs, medication expenses, adverse events costs). Effectiveness and epidemiologic 
data were retrieved from published literature. Local costs (2013 US$) were gathered 
from the official databases of Jamaican Health System. Monte Carlo probabilistic 
sensitivity analysis (PSA) was constructed. Results: Linezolid resulted as the most 
effective and less expensive option for VAP adult patients. Clinical success rate was 
higher with linezolid (64.4%) against vancomicyn (56.1%). Mean expected ICU LOS 
was 14 days for linezolid and 17 days for vancomycin, ward LOS was 14 and 24 days 
with linezolid and vancomycin, respectively. Mortality rate was found lower in the 
linezolid arm (10.13%) in comparison to vancomycin (15.74%). Overall costs per patient 
were $36721.65 with linezolid and $40776.82 with vancomycin. In the CE incremental 
analysis, linezolid appeared as the cost-saving option. PSA outcomes support the 
robustness of these findings. cOnclusiOns: Linezolid resulted as the cost-saving 
therapy for treating VAP adult patients in Jamaica.
PIN65
Cost effeCtIveNess aNalysIs of BoCePrevIr (BoC) added to PeGIfN/
rIBavIrIN (P/r) versus PeGIfN/rIBavIrIN (CurreNt staNdard of Care) for 
tHe treatmeNt of PatIeNts wItH GeNotyPe 1 CHroNIC HePatItIs C IN 
GreeCe
Athanasakis K.1, Karampli E.1, Retsa M.P.2, Theodoropoulou T.2, Kyriopoulos J.1
1National School of Public Health, Athens, Greece, 2MSD Hellas, Athens, Greece
Objectives: Boceprevir plus P/R has demonstrated a superior clinical profile, com-
pared to P/R alone, in the treatment of genotype 1 chronic hepatitis C (G1-CHC) 
patients. The objective of this study was to evaluate the cost-effectiveness of 
BOC/P/R therapy for treatment naïve and treatment experienced G1-CHC patients 
in Greece. MethOds: A Markov-model simulating the quality-adjusted life years 
and corresponding costs of G1-CHC treatment provided the basis of the analyses. 
The BOC/P/R regimens recommended in the label for treatment naïve and treat-
ment experienced patients were compared to P/R to calculate incremental costs and 
outcomes. The inputs for the model were derived from post-hoc subset analyses of 
SPRINT-2 and RESPOND-2 data. Resource use for patient monitoring and treatment 
of events was elicited via expert panel. Lifetime horizon with 3% discount rate was 
used and the perspective of analysis was third-party payers. Results: BOC-based 
therapy was projected to reduce liver complications (decompensated cirrhosis, hepa-
tocellular carcinoma, liver transplant and liver–related death) by 44% and 49-53% 
in treatment naïve and experienced patients, respectively, leading to correspond-
ing gains of 0.87 and 1.25 QALYs per patient. Taking into account medication costs, 
treatment and management of events, the ICER for BOC-based therapy versus P/R 
were estimated at 10,003€ /QALY and 10,852€ /QALY for treatment naïve and expe-
rienced patients, respectively. Extensive sensitivity analyses indicated that results 
were robust. cOnclusiOns: Based on the results of this analysis, the addition of 
Boceprevir to P/R for treatment of G1 CHC patients can be a cost-effective treatment 
option in the Greek health care setting.
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per equivalents will be recouped in less than two months. Over 5 years there were 
325 fewer infections in the copper arm at a cost per QALY of £262.84. cOnclusiOns: 
The investigation allowed the derivation of a spreadsheet-based model that uses 
the best current published information and shows the rapid ROI of a copper inter-
vention. It also calculates the impact on bed days and quality-adjusted life years 
(QALY). The model is simple, transparent to those with knowledge of spreadsheets, 
and allows adaptation to specific local settings.
PIN72
Cost-effeCtIveNess of a 13-valeNt CoNjuGate PNeumoCoCCal 
vaCCINatIoN ProGram IN CoPd PatIeNts aGed ≥ 50 years IN sPaIN: 
PrelImINary results
Menendez R.1, Rodríguez-GonzálezMoro J.M.2, Gros B.3, Echave M.3, Oyagüez I.3, Lwoff N.4, 
Egea-García M.4, Guijarro P.4
1Respiratory Infections Health La Fe Research Institute, Valencia, Spain, 2Hospital Gregorio 
Marañón, Madrid, Spain, 3Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain, 
4Pfizer Spain, Alcobendas, Spain
Objectives: Patients with chronic obstructive pulmonary disease (COPD) are at risk 
of pneumococcal infection. A 13-valent pneumococcal-conjugate vaccine (PCV13) 
has recently been approved for adult protection against S. pneumoniae. This study 
estimated the clinical and economic consequences of vaccinating COPD patients 
aged ≥ 50 years with PCV13 compared to current vaccination recommendations using 
a 23-valent pneumococcal-polysaccharide vaccine, from the Spanish Healthcare 
System perspective. MethOds: A microsimulation model with a Markov process 
accounting for risks and costs for invasive pneumococcal disease (IPD) and all-cause 
nonbacteremic pneumonia (NBP) was developed. Prevalence, mortality rates, vaccina-
tion and serotype coverage, and vaccination and disease-related costs (€ 2013) were 
based on published data. Vaccines effectiveness was modified by a waning effect 
over time. Herd-immunity and revaccination were not considered. Outcomes and 
costs (both discounted at 3%/year) were simulated 100 times with, 1.6 million COPD 
patients per simulation. Outcomes were pneumococcal cases averted and incremen-
tal cost–effectiveness ratio (ICER) in terms of cost per life-year gained (LYG). Sensitivity 
analyses were performed modifying the time horizon, discount rate and vaccination 
coverage. Results: Over a 5-year period, the use of PCV13 vs current vaccination 
strategy in adult COPD subjects would prevent 529 IPD cases, 6,329 inpatient-NBP 
cases, and 697 outpatient-NBP cases. Additionally, 231 IPD and 148 inpatient-NBP 
related deaths would be averted. The ICER was € 24,557/LYG for PCV13 vs current 
vaccination strategy. In sensitivity analyses, ICER ranged from € 26,986/LYG (when 
changing discount rate from 3% to 5%) to € 7,661/LYG (when changing vaccination 
coverage from 80% to 66%). Using a lifetime horizon 1,271 IPD cases, 10,294 inpatient-
NBP cases, and 2,072 outpatient-NBP cases would be prevented, with an ICER of € 5,030/
LYG. cOnclusiOns: At a willingness-to-pay of € 30,000/LYG, PCV13 vaccination in 
COPD patients aged ≥ 50 years in Spain is a cost-effective strategy compared to cur-
rent vaccination recommendations under both 5-year and lifetime time horizons.
PIN73
lINezolId for tHe treatmeNt of PatIeNts wItH CoNfIrmed mrsa 
NosoComIal PNeumoNIa IN NaNjING, CHINa: a Cost effeCtIve 
alterNatIve to vaNComyCIN
Tan S.C.1, Li Q.2, Chen Y.3, Hájek P.4, Weinstein D.5, Patel D.A.6
1Double Helix Consulting, Asia-Pacific, Singapore, Singapore, 2Jiangsu Province Hospital, Nanjing, 
China, 3Pfizer Inc., Beijing, China, 4Pfizer, Praha, Czech Republic, 5Pfizer Inc., Paris, France, 
6Pharmerit International, Bethesda, MD, USA
Objectives: Vancomycin has been the treatment of choice for several years while lin-
ezolid is a relatively new alternative in China. Although clinical superiority of linezolid 
was demonstrated in a recent head-to-head clinical study, economic evaluation com-
paring the two treatments provides additional useful decision making information. 
This study aimed to compare the cost-effectiveness of linezolid versus vancomycin 
in treating confirmed MRSA NP from a payer’s perspective in Nanjing. MethOds: 
A cost-effectiveness model primarily driven by the head-to-head clinical data 
(Wunderink, CID: 2012), was adapted with local published data and expert opinion 
on resource use and unit costs. The model structure and assumptions were verified 
to reflect local clinical practice. Both linezolid and vancomycin arms were assumed 
to have same life expectancy in full health upon discharge. The base case analysis 
considered 10-day treatment duration for both treatments. Scenario analyses were 
conducted by varying treatment duration, per day total costs in ICU and general ward, 
drug acquisition costs, and including costs for managing key adverse events. All costs 
were reported in 2012 Chinese RMB. Results: A higher treatment success rate by 
2.7% was predicted for linezolid. Both treatment arms were estimated to have very 
similar average total costs in the region of RMB 78,800 with the key cost drivers being 
drug acquisition costs and ICU per day total cost. The ICER for linezolid was RMB 163 
for each additional successfully treated patient. Dominance of linezolid attributed to 
greater treatment success but lower total cost was observed in most of the scenario 
analyses. The highest ICER was RMB 31,663 in the scenario where the acquisition cost 
of vancomycin reduced by 20%. cOnclusiOns: Given the estimated low ICERs with 
dominance in most of the scenario analyses, linezolid can be considered a cost effec-
tive option compared to vancomycin in managing confirmed MRSA NP in Nanjing.
PIN74
a Cost-effeCtIveNess aNalysIs of lINezolId versus vaNComyCIN for 
veNtIlator-assoCIated PNeumoNIa PatIeNts IN Costa rICa
Garita M.1, Solano A.2, Cuesta G.3, Mould J.4
1Pfizer Central America and Caribbean, Escazu, San Jose, Costa Rica, 2Hospital Dr. Rafael Ángel 
Calderón Guardia, San Jose, Costa Rica, 3Pfizer Central America and the Caribbean, Escazú, San 
Jose, Costa Rica, 4Pfizer, New York, NY, USA
Objectives: Ventilator-associated pneumonia (VAP) is the most common nosocomial 
infection in the intensive care unit (ICU). It’s associated with significant morbid-
ity, increasing the ICU and hospital length of stay (LOS), and raising overall costs. 
Literature suggests that costs could be reduced using the most efficient empiric 
recommendation on health care spending per QALY gained, PCV13 NIP in Czech 
Republic can be considered cost-effective.
PIN69
eCoNomIC evaluatIoN of fIdaxomICIN for tHe treatmeNt of 
ClostrIdIum dIffICIle INfeCtIoNs (CdI) also kNowN as C. dIffICIle-
assoCIated dIarrHoea (Cdad) IN IrelaNd
Van Engen A.1, Casamayor M.2, Loftus F.3, Crimin E.3, Lacey L.4
1Quintiles, Hoofddorp, The Netherlands, 2Quintiles, Barcelona, Spain, 3Astellas Pharma Co Ltd., 
Dublin, Ireland, 4Lacey Solutions Ltd., Skerries, Ireland
Objectives: Fidaxomicin is the first in a new class of macrocylic antibiotics, indi-
cated in adults for the treatment of Clostridium difficile infections (CDI) also known 
as C. difficile-associated diarrhoea (CDAD). The study objective was to perform a 
cost-utility analysis of fidaxomicin for the treatment of CDI compared to oral met-
ronidazole (used to treat initial non-severe CDI and first non-severe recurrence) and 
oral vancomycin (used to treat severe CDI and any non-severe recurrence beyond 
the first one). MethOds: A Markov model was used to determine the cost-utility 
of fidaxomicin in the treatment of all adult CDI patients (base case), patients with 
severe CDI, and patients with initial CDI recurrences, respectively. The cycle length 
was 10 days. The patient enters the model in the CDI health state and is treated either 
with fidaxomicin, oral metronidazole or vancomycin for 10 days. The time horizon 
was one-year. Deterministic and probabilistic sensitivity analyses were performed. 
Health state utilities were derived from the literature. The perspective was that of 
the Irish Health Service Executive (HSE). Results: In the base case, fidaxomicin was 
dominant compared to current standard of care, resulting in cost savings of € 2,904 
and an incremental QALY gain of 0.031. The main drivers of cost-effectiveness were 
the reduction in rate of recurrence in patients treated with fidaxomicin and the cost 
of hospitalisation. Fidaxomicin was also found to be dominant for all patient sub-
groups. The ICERs were highly sensitive to recurrence rates. The probability of the 
cost-effectiveness of fidaxomicin in all CDI patients at a willingness to pay thresh-
old of € 45,000 per QALY gained was estimated to be approx. 82%. cOnclusiOns: 
Fidaxomicin was dominant compared to current standard of care with an approx. 82% 
probability of being cost-effective in all CDI patients at a willingness to pay threshold 
of € 45,000 per QALY gained.
PIN70
a uk Case study of soCIetal aNd Herd-effeCt ImPaCt of uNIversal 
mass INflueNza vaCCINatIoN IN tHe uNIted kINGdom
Meier G.1, Van Bellinghen L.A.2, Van Vlaenderen I.2
1GlaxoSmithKline Vaccines, Wavre, Belgium, 2CHESS, Ternat, Belgium
Objectives: To demonstrate the impact of influenza vaccination in currently non-rec-
ommended populations in the UK. To understand critical elements of influenza infec-
tion (herd-effect and productivity losses) and management of disease. Management 
includes direct medical, non-medical and indirect resources. MethOds: A multi-
cohort, static, one-year Markov-model was constructed. Universal influenza mass 
vaccination of healthy individuals ≥ 6 months to ≤ 64 years was applied, using either 
trivalent (TIV) or quadrivalent (QIV) influenza vaccines. Current vaccination cover-
age rates for high risk persons were utilized as a proxy. Vaccine efficacy data were 
derived from Cochrane Databases (TIV) and meta-analyses (QIV). The impact of herd-
effect was evaluated by two different estimates from published literature, providing a 
range of results. A societal perspective was adopted and 2010 was the cost reference 
year. Results: Using the average influenza-B circulation and vaccine matching data 
of 2000 to 2010, between 71,000-82,000 additional cases will be prevented with QIV 
versus TIV in one influenza season. QIV is anticipated to prevent more medical vis-
its, complications, and hospitalisations (15,000-17,000); (8,000-9,300) and (889-1,044), 
respectively. QIV programme costs are higher due to acquisition costs compared to 
TIV, however influenza treatment and management costs are lower due to fewer 
cases/complications for direct medical, non-medical and indirect categories (absen-
teeism/presenteeism), (savings: £4,800,000-£5,700,000); (savings: £215,000-£253,000); 
(savings: £22,400,000-£26,400,000), respectively. In addition, future productivity losses 
caused by premature mortality are also minimized with maximal effect with QIV 
rather than TIV (savings: £5,100,000-£6,700,000). cOnclusiOns: Herd-effect is a well 
understood and appreciated benefit of vaccinating children and mass vaccination 
within a population. This model suggests that there are vast benefits in universal 
mass vaccination of healthy persons in the UK with QIV instead of TIV, due to greater 
health-related benefits and lower treatment-related costs. However, vaccine acquisi-
tion costs need to be considered.
PIN71
tHe eCoNomIC assessmeNt of aN eNvIroNmeNtal INterveNtIoN: 
dIsCrete dePloymeNt of CoPPer for INfeCtIoN CoNtrol IN ICus
Taylor M., Chaplin S.
York Health Economics Consortium, York, UK
Objectives: Health Economics evaluations are typically applied to medications or 
surgery costs, but this unique study has investigated the economic benefits of dis-
crete deployment of antimicrobial copper alloy touch surfaces in ICUs. Copper/cop-
per alloy surfaces have been shown to act as an adjunct to standard infection control 
practices in diverse clinical settings, continuously reducing contamination by over 
90%. A study by Salgado in 2013 investigated the use of copper surfaces in ICUs and 
reported a 58% reduction in hospital acquired infections. This study investigates the 
cost-effectiveness of this intervention. MethOds: Following an extensive literature 
review and use of expert opinion a number of factors have been considered in this 
evaluation. These are the component costs of the items used in the ICU, the cost of 
and extra day in bed due to an infection, baseline infection rates and risk reduction 
of copper items. The model is based on a single room configuration in an intensive 
care unit with 20 beds in the UK using 6 critical items - bed rails, overbed tray table, 
chair, call button, data device and IV pole. The model has been created to show the 
economic impact of an environmental intervention. Results: The model predicts 
the cost of replacing key, frequently-touched surfaces in a 20-bed UK ICU with cop-
